Poseida Therapeutics Inc. (PSTX): Price and Financial Metrics


Poseida Therapeutics Inc. (PSTX): $2.15

0.15 (+7.50%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PSTX Stock Price Chart Interactive Chart >

Price chart for PSTX

PSTX Price/Volume Stats

Current price $2.15 52-week high $11.10
Prev. close $2.00 52-week low $1.82
Day low $1.93 Volume 147,303
Day high $2.21 Avg. volume 174,657
50-day MA $3.39 Dividend yield N/A
200-day MA $5.64 Market Cap 134.82M

Poseida Therapeutics Inc. (PSTX) Company Bio


Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.


PSTX Latest News Stream


Event/Time News Detail
Loading, please wait...

PSTX Latest Social Stream


Loading social stream, please wait...

View Full PSTX Social Stream

Latest PSTX News From Around the Web

Below are the latest news stories about Poseida Therapeutics Inc that investors may wish to consider to help them evaluate PSTX as an investment opportunity.

Poseida Therapeutics Hosts Second Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations

Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the Company plans to highlight its clinical and preclinical pipeline progress during a virtual R&D Day to be held today beginning at 10:00am ET / 7:00am PT.

Yahoo | February 23, 2022

Poseida Therapeutics Appoints Brent Warner as President, Gene Therapy

Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that Brent Warner has joined the Company as President, Gene Therapy effective February 21, 2022.

Yahoo | February 22, 2022

Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced interim results from its Phase 1 clinical trial of P-PSMA-101, the Company's solid tumor autologous CAR-T product candidate to treat patients with metastatic castrate-resistant prostate cancer (mCRPC). These data are being presented today at the 2022 American Society of

Yahoo | February 17, 2022

Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it will host a virtual R&D Day at 10:00 am - 1:30 pm ET / 7:00 - 10:30 am PT on Wednesday, February 23, 2022.

Yahoo | February 9, 2022

Poseida Therapeutics names company''s President

Poseida Therapeutics (PSTX) appoints current President and Chief Business Officer, Mark Gergen, to the role of CEO effective as of February 1, 2022 and Eric Ostertag as…

Seeking Alpha | January 10, 2022

Read More 'PSTX' Stories Here

PSTX Price Returns

1-mo -27.61%
3-mo -44.01%
6-mo -68.61%
1-year -75.29%
3-year N/A
5-year N/A
YTD -68.43%
2021 -37.92%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4644 seconds.